Debiopharm Diagnostics, part of Debiopharm Group, is proud to congratulate Biocartis commitment in shipping its first Idylla instrument. Debiopharm Diagnostics is a long-time investor in Biocartis as part of Debiopharm Diagnostics' portfolio.

Idylla, Biocartis' fully automated, real-time PCR based molecular diagnostics system, is designed to offer physicians fast and easy access to clinical molecular diagnostic information, anywhere and anytime. Idylla opens the door to near-patient molecular testing, moving this essential diagnostic out of the central laboratory and nearer to the point of care, offering a great improvement in rapidity and quality of actionable results.

Idylla covers the entire process from sample to result in a time frame of 35 to 120 minutes with less than 2 minutes hands-on time. Idylla is applicable for a wide range of clinical sample types and can analyse both RNA and DNA. The fully integrated system enables clinical laboratories to perform a broad range of applications in oncology, infectious diseases and beyond. Idylla and the system's first assay, the Idylla BRAF Mutation Test, have obtained CE-IVD marking.

"Diagnostics are an important part of Debiopharm Group's development strategy because they are the foundation of the future of medicine", stated Thierry Mauvernay, Delegate of the Board, Debiopharm Group. Diagnostics allow patient stratification for better health outcomes, and cost savings for the payer, as well as a quicker development process and improved success rate for the developers.

"We strongly believe that Biocartis will be a game-changer in the Molecular Diagnostics field", commented Dr. David Deperthes, chief executive officer, of Debiopharm Diagnostics SA. "From the time of our first investment, we were completely convinced that Biocartis' technology would change the paradigm in this area with more precise and quicker tools. This will continue with all the new projects they have in their pipeline."